News and Press Releases
CFTR Modulators New England Journal of Medicine Publishes Study about VX-770 — A Promising Drug That Targets Underlying Defect in CF

The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.

Nov. 17, 2010 | 3 min read